AGENERASE
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGENERASE is an oral capsule small-molecule drug approved in 1999 by GSK. The specific indication and mechanism of action are not publicly documented in available data. It represents a legacy product from GSK's historical portfolio.
LOE Approaching
With LOE approaching and 30% competitive pressure, this product is in portfolio wind-down mode; commercial teams should expect resource reallocation and reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AGENERASE offers limited career advancement opportunities due to its LOE-approaching lifecycle and zero current job openings linked to the product. Professionals joining this team should expect focus on managing decline, optimizing margins, and transitioning to next-generation assets.
Brand ManagerCommercial Operations Manager
Worked on AGENERASE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.